ZURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zura Bio Ltd is not a strong buy for a beginner, long-term investor at this moment. While the company has ongoing clinical trials and analyst ratings are positive, the lack of significant financial growth, neutral trading sentiment, and absence of strong proprietary trading signals suggest holding off on investment for now.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 50.876, and moving averages are converging, suggesting no clear trend. Key resistance is at 6.438, and support is at 5.384. The stock shows a 30% chance of minor price movement in the next day, week, or month.
Analysts maintain Outperform ratings with a $15 price target, indicating potential long-term growth. Clinical trials for Tibulizumab and IL-17 combination candidate are ongoing, with key readouts expected in 2026.
No recent news or significant trading activity from hedge funds, insiders, or politicians. Financial performance remains weak, with no revenue and negative net income. Technical indicators show no strong upward momentum.
In Q4 2025, the company reported no revenue growth, a net income loss of -$45.88M (up 407.08% YoY), and an EPS of -0.48 (up 380% YoY). Gross margin remains at 0%.
Analysts from Oppenheimer and Wedbush maintain Outperform ratings with a $15 price target. They highlight potential long-term growth driven by clinical trial progress, but no immediate catalysts are present.
